Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders.
The psychiatric disorders are one of the most disabling illnesses in the world and represent a major problem for public health. These disorders are characterized by neuroanatomical or biochemical changes and it has been suggested that such changes may be due to inadequate neurodevelopment. Diverse alterations in the gene expression and/or serum level of specific growth factors have been implicated in the etiology, symptoms and progression of some psychiatric disorders. Herein, we summarize the latest information regarding the role of brain-derived neurotrophic factor (BDNF), epidermal growth factor (EGF), fibroblast growth factor (FGF), Insulin-like growth factor (IGF-1), neuroregulin-1 (NGR-1), erythropoietin (EPO), vascular growth factor (VEGF), transforming growth factor beta (TGF-β), nerve growth factor (NGF) and others cytokines in the pathogenesis of schizophrenia, depression, bipolar and anxiety disorders. Focusing on the role of these growth factors and their relationship with the main impairments (cognitive, emotional and social) of these pathologies. Some of these signaling molecules may be suitable biological markers for diagnosis and prognosis in cognitive, mood and social disabilities across different mental disorders.
Institute of Translational Neuroscience, Department of Neuroscience, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Guadalajara 44340, Mexico; Unidad de Atencion en Neurociencias, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Guadalajara 44340, Mexico. Electronic address: almayadira84@gmail.com.
Alma Y
AY
Galvez-Contreras
Medical Sciences PhD Program, School of Medicine, University of Colima, Colima 28040, Mexico; Laboratory of Neuroscience, School of Psychology, University of Colima, Colima 28040, Mexico.
Tania
T
Campos-Ordonez
Medical Sciences PhD Program, School of Medicine, University of Colima, Colima 28040, Mexico; Laboratory of Neuroscience, School of Psychology, University of Colima, Colima 28040, Mexico.
Veronica
V
Lopez-Virgen
Institute of Translational Neuroscience, Department of Neuroscience, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Guadalajara 44340, Mexico; Unidad de Atencion en Neurociencias, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Guadalajara 44340, Mexico.
Jesus
J
Gomez-Plascencia
Institute of Translational Neuroscience, Department of Neuroscience, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Guadalajara 44340, Mexico; Unidad de Atencion en Neurociencias, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Guadalajara 44340, Mexico.
Rodrigo
R
Ramos-Zuniga
Laboratory of Neuroscience, School of Psychology, University of Colima, Colima 28040, Mexico. Electronic address: osglez@ucol.mx.
Oscar
O
Gonzalez-Perez
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D001523:Mental Disorders / Q000378:metabolism*; D011379:Prognosis
D015415:Biomarkers; D036341:Intercellular Signaling Peptides and Proteins
Anxiety disorder; Biomarker; Bipolar disorder; Depression; Growth factors; Schizophrenia